A cellular protein whose normal function appears to suppress bone formation may be a potential new target for treating osteoporosis, according to a collaborative study led by Weill Cornell Medicine and NewYork-Presbyterian researchers.
A group of immune cells that normally protect against inflammation in the gastrointestinal tract may have the opposite effect in multiple sclerosis and other brain inflammation-related conditions, according to a new study by Weill Cornell Medicine researchers.
A Cornell-led collaboration is flipping the switch on traditional synthetic chemistry by using electricity to drive a new chemical reaction that previously stumped chemists.
Serving residents of two upstate New York counties, the HOPES program led by Rana Zadeh is providing secure medication organizers and training to help prevent potentially dangerous and costly mishaps.
A universal influenza vaccine developed with the potential to be longer lasting and more effective than commercially available vaccines is destined for human clinical trials, thanks to a $17.9 million grant from the National Institute of Allergy and Infectious Diseases.
Dr. Rainu Kaushal, chair of the Department of Healthcare Policy and Research at Weill Cornell Medicine, has been elected to the National Academy of Medicine
Renerva, a medical startup developing an injectable gel to speed the healing of damaged nerves and creating a nerve-graft product, has joined Cornell’s McGovern Center.
Many Americans remain confused about when COVID-19 vaccines provide strong protection and the need for continued public health precautions, according to new Cornell research.
By editing specialized genes into laboratory fruit flies, scientists have reconstructed evolution and instantly conferred in the flies the same toxin resistance enjoyed by monarch butterflies.